TCGA-22-4605-01A-21R-2125-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.460
- HEDGEHOG_SIGNALING+0.430
- APICAL_SURFACE+0.420
- COAGULATION+0.420
- INFLAMMATORY_RESPONSE+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- ESTROGEN_RESPONSE_EARLY+0.380
- HYPOXIA+0.360
Top 10 suppressed
- E2F_TARGETS-0.490
- INTERFERON_ALPHA_RESPONSE-0.440
- MYC_TARGETS_V1-0.370
- G2M_CHECKPOINT-0.360
- DNA_REPAIR-0.300
- MYC_TARGETS_V2-0.300
- INTERFERON_GAMMA_RESPONSE-0.240
- OXIDATIVE_PHOSPHORYLATION-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.180
- PI3K_AKT_MTOR_SIGNALING-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-7731-01A-11R-2125-07 | — | cohortSQ1 | 0.917 |
| 2 | SRR8613716 | — | C | 0.904 |
| 3 | SRR8613813 | — | D | 0.899 |
| 4 | MNG115 | — | — | 0.895 |
| 5 | MBCproject_0031_T1_RNA | — | A | 0.892 |
| 6 | MNG350 | — | — | 0.890 |
| 7 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.888 |
| 8 | MNG119 | — | — | 0.883 |
| 9 | SRR25617877 | — | A | 0.882 |
| 10 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.420 | Temsirolimus | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |